Operator-Led Strategic Planning for Biopharma Companies
Strategic planning is the highest-leverage activity a biopharma CEO can undertake - and the most frequently done poorly. Research by McKinsey shows that companies with formalized strategic planning processes grow 30% faster than those operating reactively, yet fewer than 20% of biopharma companies at the growth stage have a documented strategic plan updated within the past 12 months.
The stakes in 2026 are particularly high. A USD 200–400 billion patent cliff is forcing large acquirers to move aggressively, biopharma M&A spend nearly doubled in 2025 according to IQVIA, and the FDA approved a record 18 biosimilars - reshaping competitive dynamics across generics, specialty pharma, and novel therapeutics simultaneously. Growth-stage and mid-sized biopharma companies that enter this environment without a clear, operator-tested strategic roadmap will be outmaneuvered by those that do.
Drawing on 35+ years of operator experience, including CEO roles at Alvogen, a global generics and specialty pharmaceutical company operating in 35+ markets, and Cybin, a clinical-stage psychedelic medicine company listed on the NASDAQ. Every strategic plan Katogen delivers is designed to be executed, not presented.
What We Do
Board and Investor Alignment
We help CEOs and executive teams translate strategy into narratives that align boards, attract capital, and build investor confidence - drawing on direct experience as a board member, CEO, and capital raiser.
Strategic Roadmap Development
We work with your executive team to build a clear, prioritized roadmap from where you are to where you need to be. That means honest assessment of your current position, identification of the key strategic choices ahead, and a plan that is ambitious enough to create real value and realistic enough to execute.
Portfolio Prioritization
Which assets do you advance? Which partnerships do you pursue? Which markets do you enter first? We help leadership teams make these decisions with rigor and conviction — not by consensus or inertia.
Competitive Positioning
We analyze your competitive landscape with the same depth a sophisticated acquirer or investor would apply - and help you build a positioning strategy that differentiates you meaningfully in a crowded field.
organizational development
Strategy, without the right organizational structure, is a document, not a plan. We help you design the leadership team, governance model, and operating cadence needed to execute at the pace your strategy demands.
Built for the Operator's Seat
Who This Is For?
This service is designed for CEOs and executive teams at growth-stage and mid-sized biopharma and life sciences companies facing a strategic inflection point — a new financing round, a pipeline decision, a market entry, a leadership transition, or simply the recognition that the current strategy is not working fast enough.
Why Katogen?
Most strategy advisors approach biopharma from the outside - with frameworks, benchmarks, and slide templates. Katogen approaches it from the inside - with 35+ years of experience sitting in the CEO chair, making the same decisions you are facing now.
That means our strategic plans are designed to be executed, not presented. Every recommendation is grounded in operational reality, not theoretical optionality.
WORK WITH KATOGEN
If you are navigating a strategic inflection point — a capital raise, an acquisition, a turnaround, a regulatory challenge, or simply a moment where you need an experienced operator in your corner — we would welcome the conversation. Engagements are selective. The first step is a direct conversation to understand your situation and determine where Katogen can add the most value.
